- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Aimee Tharaldson: Orphan Drugs Will Remain A Lucrative, Growing Business
Orphan drugs are a very lucrative business, and Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, expects to see more orphan drugs reach market as manufacturers focus their development efforts in these areas.
Orphan drugs are a very lucrative business, and Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapies at Express Scripts, expects to see more orphan drugs reach market as manufacturers focus their development efforts in these areas.
Transcript (slightly modified)
In 2015, the majority of specialty drugs were approved for orphan indications. Do you see that trend continuing?
In 2015, two-thirds of the specialty drugs approved were for orphan conditions. I think that’s high. I think, going forward, we’ll maybe see that closer to half, but yes, orphan medications is really where many manufacturers are focusing their development efforts.
These medications have 7 years of patent exclusivity and other financial incentives. Obviously, they’re very expensive; they cost about $300,000 per year or more depending. So they’re very expensive medications, and actually about 30% of all orphan medications become blockbuster medications with annual sales greater than $1 billion.
It’s very lucrative for manufacturers to develop orphan drugs so yes, I think that’s going to be a continuing trend that we’ll see more and more orphan drugs reaching the market.
Dr Kathryn Lindley Explains the Importance of Cardio-Obstetrics in Fellowship Programs
December 5th 2023Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, talks about why it’s important to incorporate cardio-obstetrics training into cardiovascular disease fellowship programs.
Read More
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Christine Pfaff on Ensuring Patient Access to Affordable Treatments
October 17th 2023To ensure patients are getting timely access to their treatments, there needs to be better collaboration between payers and providers, said Christine Pfaff, RPh, senior regional director of operations, American Oncology Network.
Read More
